Cassava Sciences Reports Full-year 2023 Financial Results :

$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over...

Related Keywords

Canada , Texas , United States , Puerto Rico , France , Australia , South Korea , New York , Pierre Gravier , Remi Barbier , Eric Schoen , Robert Anderson Jr , Cassava Sciences Inc , Cochin Institute Paris , City University Of New York , Drug Administration , Nasdaq , Orrick Herrington Sutcliffe , Cassava Sciences , Company Board Of Directors , Research International , Clinical Program , Cash Equivalents , Participants Have Completed Our Phase , Data Readout , Week Phase , Expected Year End , Outside Counsel Has Found No Evidence , Substantiate Allegations , Research Misconduct , Cassava Science , Chief Financial , Clause Nicaise , Robert Anderson , Safety Monitoring Board , Cassava Science Phase , Cochin Institute , Premier Research International , Clinical Dementia Rating , Global Scale , Baseline Characteristics , Analysis Plan , Extension Study , City University , Orrick Herrington , More Information Contact , Note Regarding Forward Looking Statements , Private Securities Litigation Reform Act , Annual Report , Financial Tables Follow , Ended December ,